International Journal of Gynecological Cancer最新文献

筛选
英文 中文
Clinical value of circulating tumor DNA for patients with epithelial ovarian cancer. 循环肿瘤DNA在上皮性卵巢癌患者中的临床价值。
IF 4.1 2区 医学
International Journal of Gynecological Cancer Pub Date : 2025-07-01 Epub Date: 2025-05-10 DOI: 10.1016/j.ijgc.2025.101925
Émilie Laude, Henri Azaïs, Mehdi Ben Sassi, Anne-Sophie Bats, Valérie Taly, Pierre Laurent-Puig
{"title":"Clinical value of circulating tumor DNA for patients with epithelial ovarian cancer.","authors":"Émilie Laude, Henri Azaïs, Mehdi Ben Sassi, Anne-Sophie Bats, Valérie Taly, Pierre Laurent-Puig","doi":"10.1016/j.ijgc.2025.101925","DOIUrl":"10.1016/j.ijgc.2025.101925","url":null,"abstract":"<p><p>Despite progress in recent years, epithelial ovarian cancer remains a pathology with a poor prognosis, primarily because of late and invasive diagnosis. Conventional follow-up relies on imaging, CA125, and predictive tools such as KELIM-CA125 and the chemotherapy response score. However, these methods are non-specific and result in delays before obtaining results. Recently, many research teams have focused on liquid biopsies, which provide direct access to tumor material in biological fluids. This review examines the clinical potential of circulating tumor DNA (ctDNA) in epithelial ovarian cancer. A systematic search of the PubMed database was conducted. Inclusion criteria were studies published in English, original research articles, reviews, or meta-analyses focused on ctDNA and ovarian cancer. Exclusion criteria included non-peer-reviewed sources, articles with insufficient data, and studies not directly related to the topic. In epithelial ovarian cancer, ctDNA allows quantitative evaluation of tumor burden and qualitative analysis by detecting specific tumor DNA variations, such as epigenetic modifications or genetic mutations. Furthermore, its half-life is less than 2 hours, enabling dynamic monitoring of tumor evolution. This capability could facilitate earlier diagnosis, better screening, and more effective therapeutic follow-up. The qualitative approach also has the potential to predict chemoresistance. Technologies used to detect ctDNA in blood include quantitative polymerase chain reaction, digital polymerase chain reaction, and next-generation sequencing, which allow quantification and identification of DNA molecule modifications. CtDNA is a promising biomarker for epithelial ovarian cancer and could address several challenges in its management. However, further research is needed to establish its role in routine clinical practice, particularly, to identify a detection method that is highly sensitive, specific, and generalizable to a wide patient population.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 7","pages":"101925"},"PeriodicalIF":4.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144158586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to 'Cytoreductive surgery in advanced epithelial ovarian cancer: a real-world analysis guided by clinical variables, homologous recombination, and BRCA status' [International Journal of Gynecological Cancer Volume 35 Issue 6 (2025) 101809]. 对“晚期上皮性卵巢癌的细胞减少手术:由临床变量、同源重组和BRCA状态指导的现实世界分析”的更正[International Journal of Gynecological cancer卷35第6期(2025)101809]。
IF 4.1 2区 医学
International Journal of Gynecological Cancer Pub Date : 2025-07-01 Epub Date: 2025-06-11 DOI: 10.1016/j.ijgc.2025.101958
Eliya Shachar, Yael Raz, Gilat Rotkop, Uriel Katz, Ido Laskov, Nadav Michan, Dan Grisaru, Ido Wolf, Tamar Safra
{"title":"Corrigendum to 'Cytoreductive surgery in advanced epithelial ovarian cancer: a real-world analysis guided by clinical variables, homologous recombination, and BRCA status' [International Journal of Gynecological Cancer Volume 35 Issue 6 (2025) 101809].","authors":"Eliya Shachar, Yael Raz, Gilat Rotkop, Uriel Katz, Ido Laskov, Nadav Michan, Dan Grisaru, Ido Wolf, Tamar Safra","doi":"10.1016/j.ijgc.2025.101958","DOIUrl":"10.1016/j.ijgc.2025.101958","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 7","pages":"101958"},"PeriodicalIF":4.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144283859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic value of isolated tumor cells in sentinel lymph nodes in intermediate-risk endometrial cancer: results from an international, multi-institutional study. 中危子宫内膜癌前哨淋巴结分离肿瘤细胞的预后价值:来自一项国际、多机构研究的结果
IF 4.1 2区 医学
International Journal of Gynecological Cancer Pub Date : 2025-07-01 Epub Date: 2025-04-28 DOI: 10.1016/j.ijgc.2025.101906
Giuseppe Cucinella, Gabriella Schivardi, Xun Clare Zhou, Mariam M AlHilli, Sumer Wallace, Allan Covens, Christoph Wohlmuth, Glauco Baiocchi, Nedim Tokgozoglu, Francesco Raspagliesi, Alessandro Buda, Vanna Zanagnolo, Ignacio Zapardiel, Nisha Jagasia, Robert Giuntoli, Ariel Glickman, Michele Peiretti, Maximillian Lanner, Enrique Chacon, Julian Di Guilmi, Augusto Pereira, Enora Laas, Ami Fishman, Caroline C Nitschmann, Katherine Kurnit, Kristen Moriarty, Amy Joehlin-Price, Brittany Lees, Louise De Brot, Cagatay Taskiran, Giorgio Bogani, Fabio Landoni, Luis Chiva, Tommaso Grassi, Tommaso Bianchi, Francesco Multinu, Luigi Antonio De Vitis, Alicia Hernandez-Gutierrez, Spyridon Mastroyannis, Khaled Ghoniem, Emilia Palmieri, Vito Chiantera, Shahi Maryam, Angela J Fought, Michaela E McGree, Andrea Mariani, Gretchen Glaser
{"title":"Prognostic value of isolated tumor cells in sentinel lymph nodes in intermediate-risk endometrial cancer: results from an international, multi-institutional study.","authors":"Giuseppe Cucinella, Gabriella Schivardi, Xun Clare Zhou, Mariam M AlHilli, Sumer Wallace, Allan Covens, Christoph Wohlmuth, Glauco Baiocchi, Nedim Tokgozoglu, Francesco Raspagliesi, Alessandro Buda, Vanna Zanagnolo, Ignacio Zapardiel, Nisha Jagasia, Robert Giuntoli, Ariel Glickman, Michele Peiretti, Maximillian Lanner, Enrique Chacon, Julian Di Guilmi, Augusto Pereira, Enora Laas, Ami Fishman, Caroline C Nitschmann, Katherine Kurnit, Kristen Moriarty, Amy Joehlin-Price, Brittany Lees, Louise De Brot, Cagatay Taskiran, Giorgio Bogani, Fabio Landoni, Luis Chiva, Tommaso Grassi, Tommaso Bianchi, Francesco Multinu, Luigi Antonio De Vitis, Alicia Hernandez-Gutierrez, Spyridon Mastroyannis, Khaled Ghoniem, Emilia Palmieri, Vito Chiantera, Shahi Maryam, Angela J Fought, Michaela E McGree, Andrea Mariani, Gretchen Glaser","doi":"10.1016/j.ijgc.2025.101906","DOIUrl":"10.1016/j.ijgc.2025.101906","url":null,"abstract":"<p><strong>Objective: </strong>This study assessed oncologic outcomes of patients with intermediate-risk endometrioid endometrial cancer and isolated tumor cells (ITC) (≤0.2 mm or ≤200 cells) in sentinel lymph nodes (SLNs).</p><p><strong>Methods: </strong>Patients with SLN-ITC diagnosed between 2012 and 2019 were identified from 19 centers worldwide, while SLN-negative patients were identified at Mayo Clinic, Rochester between 2014 and 2018. Only patients with endometrioid endometrial cancer and intermediate-risk factors (low-grade endometrioid histology and myometrial invasion ≥50%; high-grade endometrioid histology and myometrial invasion <50%) were included. Oncologic outcomes were evaluated by grouping patients according to prognostic factors: SLN-ITC and lymphovascular space invasion (LVSI). SLN-ITC patients with post-operative observation or vaginal brachytherapy (VB) alone were compared with similar node-negative patients.</p><p><strong>Results: </strong>Of the 166 patients included, those with simultaneous presence of SLN-ITC and LVSI were at higher risk of non-vaginal recurrence (HR 3.73 [95% CI 1.17 to 11.84], p = .01) compared with patients who were node-negative with no LVSI. Among the 122 patients (28 SLN-ITC, 94 node-negative) who underwent post-operative observation or VB alone, 1 isolated vaginal recurrence was documented in a node-negative patient, while non-vaginal recurrence occurred in 3 of 28 (10.7%) SLN-ITC and 7 of 94 (7.4%) node-negative patients. The median follow-up was 2.4 years (interquartile range; 1.8-3.0) among the remaining 25 ITC patients and 2.8 years (interquartile range; 0.8-4.2) among the remaining 87 node-negative patients. There was no difference in non-vaginal recurrence-free survival (SLN-ITC: 87.3% [95% CI 74.7% to 100.0%] vs node-negative: 82.2% [95% CI 69.1% to 97.9%], p = .46) or overall survival (SLN-ITC: 76.4% [95% CI 54.3 to 100.0] vs node-negative: 84.5% [95% CI 75.0 to 95.2], p = .28) between the 2 cohorts.</p><p><strong>Conclusions: </strong>In patients with endometrioid endometrial cancer and intermediate-risk factors (including patients who received chemotherapy/external beam radiotherapy), the combination of SLN-ITC and LVSI was associated with worse prognosis compared with patients with no risk factors or only 1 risk factor. In the sub-group of patients who received post-operative observation or VB alone, SLN-ITC did not worsen prognosis relative to node-negative patients.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 7","pages":"101906"},"PeriodicalIF":4.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ROCC/GOG-3043: a randomized controlled trial of robotic versus open surgery for early-stage cervical cancer. ROCC/GOG-3043:早期宫颈癌机器人手术与开放手术的随机对照试验
IF 4.1 2区 医学
International Journal of Gynecological Cancer Pub Date : 2025-07-01 Epub Date: 2025-02-28 DOI: 10.1016/j.ijgc.2025.101760
Mario M Leitao, Kristin L Bixel, Dana Meredith Chase, Allison Quick, Colleen McCormick, Destin Black, Peter C Lim, Ramez N Eskander, Walter H Gotlieb, Salvatore LoCoco, Martin A Martino, Joan L Walker, Larry J Copeland, Bradley J Monk, Leslie M Randall
{"title":"ROCC/GOG-3043: a randomized controlled trial of robotic versus open surgery for early-stage cervical cancer.","authors":"Mario M Leitao, Kristin L Bixel, Dana Meredith Chase, Allison Quick, Colleen McCormick, Destin Black, Peter C Lim, Ramez N Eskander, Walter H Gotlieb, Salvatore LoCoco, Martin A Martino, Joan L Walker, Larry J Copeland, Bradley J Monk, Leslie M Randall","doi":"10.1016/j.ijgc.2025.101760","DOIUrl":"10.1016/j.ijgc.2025.101760","url":null,"abstract":"<p><strong>Background: </strong>The Laparoscopic Approach to Cervical Cancer trial is the only randomized trial to date addressing the role of surgical approach in cervical cancer; however, this non-inferiority trial of minimally invasive surgery vs an open approach in patients undergoing radical hysterectomy for early-stage cervical cancer did not meet its primary end point of 4.5-year disease-free survival and was terminated early because of significantly worse disease-specific survival, overall survival, and locoregional recurrence in the minimally invasive surgery cohort.</p><p><strong>Primary objective: </strong>Our trial compares 3-year disease-free survival after robotic-assisted or abdominal radical or simple (in select cases) hysterectomy in early-stage cervical cancer.</p><p><strong>Study hypothesis: </strong>We hypothesize that disease-free survival is non-inferior after robotic-assisted vs abdominal radical or simple hysterectomy.</p><p><strong>Trial design: </strong>This multi-center, randomized non-inferiority trial conducted through the Gynecologic Oncology Group has specified surgeon qualification criteria. It requires a pelvic magnetic resonance imaging scan in all patients before enrollment and will use 1:1 randomization to assign patients to robotic-assisted or abdominal hysterectomy. All surgeons must use specified tumor-containment techniques in both arms. It does not allow trans-cervical uterine manipulators.</p><p><strong>Major inclusion/exclusion criteria: </strong>Patients with early-stage (2018 International Federation of Gynecology and Obstetrics stages IA2-IB2) cervical cancer. Histologic types are limited to squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma. Pelvic magnetic resonance imaging must confirm a tumor that is 4 cm or less without definitive extra-cervical spread. A simple hysterectomy is allowed in select cases after trial study principal investigator review.</p><p><strong>Primary endpoint: </strong>The primary end point is the 3-year disease-free survival between robotic-assisted or abdominal hysterectomy.</p><p><strong>Sample size: </strong>The trial will randomly allocate 840 patients, with planned interim analysis for futility (oncologic safety) after we have randomly allocated 370 and 640 patients.</p><p><strong>Estimated dates for completing accrual and presenting results: </strong>2030.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov identifier: NCT04831580.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101760"},"PeriodicalIF":4.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143788305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of homologous recombination deficiency among women with newly diagnosed ovarian, primary peritoneal, and/or fallopian tube cancer: the international HALO study. 在新诊断的卵巢癌、原发性腹膜癌和/或输卵管癌的女性中,同源重组缺乏的患病率:国际HALO研究
IF 4.1 2区 医学
International Journal of Gynecological Cancer Pub Date : 2025-07-01 Epub Date: 2025-01-17 DOI: 10.1016/j.ijgc.2025.101645
Svetlana Khokhlova, Manwar Abdulelah Alnaqqash, Waleed Bahaj, Salha Bujassoum, Jooyeon Lee, Mohsen Mokhtar, Alexandra Tyulyandina, Carmen Luz Vargas Malaga, Chen-Hsuan Wu
{"title":"Prevalence of homologous recombination deficiency among women with newly diagnosed ovarian, primary peritoneal, and/or fallopian tube cancer: the international HALO study.","authors":"Svetlana Khokhlova, Manwar Abdulelah Alnaqqash, Waleed Bahaj, Salha Bujassoum, Jooyeon Lee, Mohsen Mokhtar, Alexandra Tyulyandina, Carmen Luz Vargas Malaga, Chen-Hsuan Wu","doi":"10.1016/j.ijgc.2025.101645","DOIUrl":"10.1016/j.ijgc.2025.101645","url":null,"abstract":"<p><strong>Objective: </strong>The HALO study (NCT04991051) determined the prevalence of homologous recombination deficiency and its associated factors in patients with high-grade serous/endometrioid ovarian, primary peritoneal, and/or fallopian tube cancers across Asia, the Middle East, and Russia.</p><p><strong>Methods: </strong>This multinational, cross-sectional, real-world study enrolled adult women with newly diagnosed stage III or IV high-grade serous/endometrioid ovarian, primary peritoneal, and/or fallopian tube cancers. Formalin-fixed paraffin-embedded tumor blocks were collected within 120 days of enrollment. The prevalence of homologous recombination deficiency, high genomic instability score (GIS) without tumor BRCA mutations, and BRCA mutations were evaluated along with patient characteristics. Factors associated with homologous recombination deficiency, high GIS without BRCA mutations, and BRCA mutations were identified using a logistic-regression model.</p><p><strong>Results: </strong>Of the 734 patients (median [range] age; 59.0 [23.0-89.0] years), most (92.9%) had a primary ovarian tumor, followed by primary peritoneal (4.1%) and fallopian tube cancers (3.0%). Of the tested 662 patients; 56.0% (371) were homologous recombination deficiency-positive (Asia, 52.0%; the Middle East, 52.2%; Russia, 58.5%). Overall, 204 (30.8%) patients had a high GIS without BRCA mutations (Middle East, 23.9%; Russia, 31.9%; Asia, 41.3%), and 167 (25.2%) had BRCA mutations (Asia, 10.7%; Russia, 26.6%; Middle East, 28.3%). Patients with 1 comorbidity versus no comorbidities (96 vs 207, OR 1.54), a family history of genetically-related cancers versus no family history of cancer (82 vs 224, OR 2.64), and contraceptive use versus no history of contraceptive use (47 vs 323, OR 2.04) were more likely to have homologous recombination deficiency.</p><p><strong>Conclusions: </strong>This real-world study reported a homologous recombination deficiency prevalence of 56.0% (ranging from 52.0% to 58.5%) across Asia, the Middle East, and Russia. Our results highlight the unmet need to implement guideline-recommended testing and real-world data collection for all patients newly diagnosed with advanced high-grade epithelial ovarian cancer to optimize treatment strategies.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101645"},"PeriodicalIF":4.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143597121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The art of prevention: merging creativity and medicine to transform cervical cancer awareness. 预防的艺术:将创意与医学结合,转变对子宫颈癌的认识。
IF 4.1 2区 医学
International Journal of Gynecological Cancer Pub Date : 2025-07-01 Epub Date: 2025-04-26 DOI: 10.1016/j.ijgc.2025.101909
Gil Zeevi, Ram Eitan
{"title":"The art of prevention: merging creativity and medicine to transform cervical cancer awareness.","authors":"Gil Zeevi, Ram Eitan","doi":"10.1016/j.ijgc.2025.101909","DOIUrl":"10.1016/j.ijgc.2025.101909","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 7","pages":"101909"},"PeriodicalIF":4.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144110701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Highlights from the 26th European Congress on Gynaecological Oncology in Rome: interview compilation of the ENYGO-IJGC editorial fellows. 罗马第26届欧洲妇科肿瘤学大会的亮点:enigo - ijgc编辑研究员的访谈汇编。
IF 4.1 2区 医学
International Journal of Gynecological Cancer Pub Date : 2025-07-01 Epub Date: 2025-04-29 DOI: 10.1016/j.ijgc.2025.101913
Martina Aida Angeles, Esra Bilir, Ilker Kahramanoglu, Helena Obermair, Alexander Shushkevich, Núria Agustí, Aleksandra Strojna, Ana Luzarraga Aznar, David Viveros-Carreño, Nicolò Bizzarri, Andrej Cokan, Houssein El Hajj, Mathilde Del, Elena Rodríguez, Osnat Elyashiv, Stamatios Petousis, Joanna Kacperczyk-Bartnik, Manel Montesinos-Albert, Nadeem Abu-Rustum, Philipp Harter, Isabelle Ray-Coquard, Alejandra Martinez, David Cibula, Henrik Falconer, Rene Pareja, Claudia Marchetti, Murat Gultekin, Frédéric Amant, Mansoor Raza Mirza, Pedro T Ramirez
{"title":"Highlights from the 26th European Congress on Gynaecological Oncology in Rome: interview compilation of the ENYGO-IJGC editorial fellows.","authors":"Martina Aida Angeles, Esra Bilir, Ilker Kahramanoglu, Helena Obermair, Alexander Shushkevich, Núria Agustí, Aleksandra Strojna, Ana Luzarraga Aznar, David Viveros-Carreño, Nicolò Bizzarri, Andrej Cokan, Houssein El Hajj, Mathilde Del, Elena Rodríguez, Osnat Elyashiv, Stamatios Petousis, Joanna Kacperczyk-Bartnik, Manel Montesinos-Albert, Nadeem Abu-Rustum, Philipp Harter, Isabelle Ray-Coquard, Alejandra Martinez, David Cibula, Henrik Falconer, Rene Pareja, Claudia Marchetti, Murat Gultekin, Frédéric Amant, Mansoor Raza Mirza, Pedro T Ramirez","doi":"10.1016/j.ijgc.2025.101913","DOIUrl":"10.1016/j.ijgc.2025.101913","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 7","pages":"101913"},"PeriodicalIF":4.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144132280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum to 'Primary versus interval cytoreductive surgery in patients with rare epithelial or non-epithelial ovarian cancer' [International Journal of Gynecological Cancer Volume 35 Issue 3 (2025) 101664]. “罕见上皮性或非上皮性卵巢癌患者的原发性与间隔性细胞减少手术”的勘误[国际妇科癌症杂志第35卷第3期(2025)101664]。
IF 4.1 2区 医学
International Journal of Gynecological Cancer Pub Date : 2025-07-01 Epub Date: 2025-05-31 DOI: 10.1016/j.ijgc.2025.101952
Diletta Fumagalli, Aarthi Jayraj, Elena Olearo, Ilaria Capasso, Heng-Cheng Hsu, Yossi Tzur, Sabrina Piedimonte, Bella Jugeli, Beatriz Navarro Santana, Luigi Antonio De Vitis, Giuseppe Caruso, Giovanni Aletti, Nicoletta Colombo, Pedro T Ramirez
{"title":"Erratum to 'Primary versus interval cytoreductive surgery in patients with rare epithelial or non-epithelial ovarian cancer' [International Journal of Gynecological Cancer Volume 35 Issue 3 (2025) 101664].","authors":"Diletta Fumagalli, Aarthi Jayraj, Elena Olearo, Ilaria Capasso, Heng-Cheng Hsu, Yossi Tzur, Sabrina Piedimonte, Bella Jugeli, Beatriz Navarro Santana, Luigi Antonio De Vitis, Giuseppe Caruso, Giovanni Aletti, Nicoletta Colombo, Pedro T Ramirez","doi":"10.1016/j.ijgc.2025.101952","DOIUrl":"10.1016/j.ijgc.2025.101952","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 7","pages":"101952"},"PeriodicalIF":4.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144199012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Response to correspondence on prognostic value of tertiary lymphoid structures in molecular subgroups of endometrial carcinoma by Pradhan et al. Pradhan等人对子宫内膜癌分子亚群中三级淋巴结构预测预后价值的响应。
IF 4.1 2区 医学
International Journal of Gynecological Cancer Pub Date : 2025-07-01 Epub Date: 2025-06-07 DOI: 10.1016/j.ijgc.2025.101970
Manohar Pradhan, Wanja Kildal, Ljiljana Vlatkovic, Kari Anne R Tobin, Kristina Lindemann, Gunnar B Kristensen, Andreas Kleppe, Hanne A Askautrud
{"title":"Response to correspondence on prognostic value of tertiary lymphoid structures in molecular subgroups of endometrial carcinoma by Pradhan et al.","authors":"Manohar Pradhan, Wanja Kildal, Ljiljana Vlatkovic, Kari Anne R Tobin, Kristina Lindemann, Gunnar B Kristensen, Andreas Kleppe, Hanne A Askautrud","doi":"10.1016/j.ijgc.2025.101970","DOIUrl":"10.1016/j.ijgc.2025.101970","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 7","pages":"101970"},"PeriodicalIF":4.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144540084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hepatic hilum cytoreductive surgery for ovarian cancer relapse. 治疗卵巢癌复发的肝门部细胞剥脱手术
IF 4.1 2区 医学
International Journal of Gynecological Cancer Pub Date : 2025-07-01 Epub Date: 2025-04-23 DOI: 10.1136/ijgc-2024-005285
Myriam Gracia, Constantino Fondevila, Alicia Hernández, Isabel Prieto, María Alonso-Espias, Ignacio Zapardiel
{"title":"Hepatic hilum cytoreductive surgery for ovarian cancer relapse<sup>☆</sup>.","authors":"Myriam Gracia, Constantino Fondevila, Alicia Hernández, Isabel Prieto, María Alonso-Espias, Ignacio Zapardiel","doi":"10.1136/ijgc-2024-005285","DOIUrl":"10.1136/ijgc-2024-005285","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101881"},"PeriodicalIF":4.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142286480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信